Recombinetics

Recombinetics, headquartered at 3388 Mike Collins Drive, Eagan, MN, is a leader in the field of animal gene editing, utilizing its proprietary technology to enhance biomedical research, regenerative medicine, and animal agriculture. The company operates through four subsidiaries, each targeting specific applications of its gene editing technology. Following its merger with Makana Therapeutics, Recombinetics has intensified its focus on xenotransplantation to address the global organ shortage crisis. Its subsidiary, Therillume, concentrates on precision medicine solutions for brain tumors, while Acceligen leverages precision breeding techniques to improve health, welfare, and sustainability in food animals. Recombinetics has developed a robust pipeline of gene-edited animals that are already generating revenue, with more under development for both biomedical and food animal markets. The company’s extensive intellectual property includes 68 issued patents and over 190 patent applications globally, covering crucial first-use and enabling technologies in livestock gene editing using CRISPR and TALENs.